A new analysis of data from the Phase III TRITON-TIMI 38 trial has shown that patients receivingDaiichi Sankyo/Lilly's platelet inhibitor prasugrel (Effient) who survived their first cardiovascular event were 35% less likely to suffer a similar recurrent event than those on clopidogrel (Sanofi-Aventis's Plavix/Iscover).
The findings may serve to further strengthen prasugrel's eventual competitive positioning versus its main rival following the favourable results from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?